Home / 2020 / June / 03

Daily Archives: June 3, 2020

INVNT CEO, Scott Cullather Recognized as A Top Virtual Meetings and Events Innovator

New York, NY, June 03, 2020 (GLOBE NEWSWIRE) — Scott Cullather, the Co-Founder and CEO of INVNT, the global live brand storytelling agency™ has been named one of the industry’s Top 50 Virtual Meetings & Events Innovators.

An initiative from Eventex Connect, the online trade show for virtual meetings and events, this prestigious peer nominated and voted list acknowledges both the growing importance of virtual events and the innovators, change-makers and pioneers behind the shift to virtual.

It features industry leaders from agencies, brands and media outlets including Zoom, Cisco, WebEx Meetings, JoinMe and Event Industry News.

“The global pandemic made pivoting to virtual one of the hottest topics in the events industry, but the people behind these groundbreaking changes just don’t get enough recognition. We feel now is the perfect time to rectify that,” says O. Ovanessian, co-founder of Eventex.

Commenting on his inclusion in the list, Cullather adds: “I am so honored! Thank you to my peers for the recognition and the Eventex team for launching this important initiative. From livestreams to social and augmented reality (AR), many of us have been incorporating virtual into our face-to-face experiences for some time, but more than ever, we must design and produce live virtual experiences that continue to combine the best of these worlds, albeit in the comfort of our audiences homes.

“Once the pandemic ends I urge you all to continue to weave virtual throughout your face-to-face events. Not only do they provide potent amplification opportunities, our most powerful audiences – millennials and Gen Zs – are innately digital beings, and they’ll expect these phygital experiences – those that combine the best of the physical and the digital – from us.”

Cullather will be speaking at Eventex Connect 2020, which is taking place from June 10-11. In his session The broadcast, but not as you know it: how to maximize the phygital format for maximum engagement on June 11 at 1:00pm ET, Cullather will cover the shift to virtual, the phygital trend and more.

 View the entire list here: https://eventex.co/connect/top-50-innovators/

View the Eventex Connect agenda here: https://eventex.co/connect/agenda/

About INVNT
Founded in 2008 by Scott Cullather and Kristina McCoobery, INVNT is the global live brand storytelling agency™. The company’s ‘challenge everything’ positioning statement helps clients including General Motors, Grant Thornton, Merck, PepsiCo, Samsung and Subway – share their stories – live – with every audience that matters. ‘The tribe’ is INVNT’s diverse, talented and creative team behind the stories and brand experiences that people just can’t stop talking about. INVNT’s offices are strategically located in New York, where INVNT’s story studio, HEVĒ and brand strategy firm, Folk Hero are also based, London, Sydney, Detroit, San Francisco, Washington D.C., Stockholm and Singapore. For more information visit www.invnt.com

Attachments

Brea Carter
INVNT
+1 09176336171
bcarter@invnt.com

OKEx คาดว่าจะมีพนักงานเพิ่มขึ้น 100% ในอีกสองปี

มอลตา, June 03, 2020 (GLOBE NEWSWIRE) — หลังจากการแพร่ระบาดของโควิด-19 ท่ามกลางการชะลอตัวของเศรษฐกิจโลกและอัตราการว่างงานที่เพิ่มสูงขึ้น อุตสาหกรรมเงินดิจิทัลได้รับความนิยมอย่างมาก โดยเห็นได้จากจำนวนรวมของธุรกรรมที่ได้รับการยืนยันต่อวันตามข้อมูลจาก Blockchain.com ซึ่งเติบโตอย่างต่อเนื่องนับตั้งแต่การลดลงอย่างมากของ BTC ในเดือนมีนาคมจนเหลือธุรกรรมเพียงประมาณ 250K ต่อวัน ในขณะที่ปริมาณการซื้อขายรวมในการแลกเปลี่ยนบิตคอยน์ (Bitcoin) ที่สำคัญสูงถึง 684.4 ล้านเหรียญสหรัฐในเดือนมีนาคม การแพร่ระบาดของโควิด-19 เร่งการยอมรับเงินดิจิทัลอย่างไม่ต้องสงสัย รวมทั้งยังทำให้ผู้คนเริ่มหันมาไว้วางใจในบิตคอยน์มากกว่าสินทรัพย์ที่ปลอดภัยแบบดั้งเดิม เช่น ทองคำ ตลาดหุ้น และอสังหาริมทรัพย์

เมื่อพิจารณาโอกาสทางธุรกิจที่กำลังเติบโตและอุปสงค์การซื้อขายเงินดิจิทัลที่เพิ่มขึ้นแล้ว OKEx จึงกำลังขยายฐานธุรกิจไปยังภูมิภาคต่าง ๆ ของโลกนอกเหนือจาก 180 ประเทศและพื้นที่ที่มีอยู่เดิม “นี่เป็นช่วงเวลาที่น่าตื่นเต้นสำหรับ OKEx เราวางแผนที่จะเปิดสำนักงานใหม่ในภูมิภาคต่าง ๆ เพื่อให้บริการผู้ใช้ของเราได้ดียิ่งขึ้น และเราได้เริ่มสรรหาผู้เชี่ยวชาญด้านบล็อกเชนที่มีใจรักในการทำงานเพื่อเติบโตและประสบความสำเร็จไปด้วยกัน เราคาดว่าจะมีจำนวนพนักงานรวมเพิ่มขึ้น 100% ในอีก 2 ปี เพื่อให้บริการลูกค้าจากทั่วโลก” Jay Hao ประธานเจ้าหน้าที่บริหาร OKEx กล่าว

Jay ยังได้เปิดเผยอีกว่า OKEx กำลังจะเปิดตัว Beacon Program ในภูมิภาคยุโรปเพื่อสนับสนุนผู้ที่สนใจในโลกบล็อกเชนและเงินดิจิทัลที่กำลังเฟื่องฟูในช่วงล็อกดาวน์ และยังถือเป็นโอกาสที่จะได้สรรหาและอบรมคนเก่งที่จะมาร่วมงานกับ OKEx ในอนาคต

OKEx Beacon Program จะสรรหาผู้รับการสอนงานทั้งหมด 6 คน เพื่อรับการสอนงานเป็นพิเศษเป็นเวลาหนึ่งเดือนจากประธานเจ้าหน้าที่บริหาร Jay Hao และผู้อำนวยการฝ่ายตลาดการเงิน Lennix Lai โดยผู้รับการสอนงานจะได้รับการสอนงานผ่านทาง Telegram ครั้งละ 30 นาที สัปดาห์ละหนึ่งครั้ง นอกจากนี้ ผู้รับการสอนงานยังจะได้เข้าร่วมมาสเตอร์คลาสจากผู้เชี่ยวชาญในอุตสาหกรรมในหัวข้อเฉพาะเกี่ยวกับบล็อกเชนและเงินดิจิทัล รวมทั้งได้รับสรุปข่าวประจำวัน งานวิจัยอุตสาหกรรม และความรู้เกี่ยวกับผลิตภัณฑ์ทุกวัน และได้รับแนวทางจากทีม OKEx ผู้ที่ทำงานผลได้โดดเด่นจะได้รับโอกาสเข้าร่วมทีม OKEx ในอนาคต

เกี่ยวกับ OKEx

OKEx เป็นตลาดซื้อขายสกุลเงินดิจิทัลที่ใหญ่ที่สุดและหลากหลายที่สุดในโลก ซึ่งผู้ซื้อขายเงินดิจิทัล ผู้ขุด และผู้ลงทุนสถาบันทั่วโลกเข้ามาเพื่อบริหารจัดการสินทรัพย์เงินดิจิทัล เพิ่มโอกาสในการลงทุน และป้องกันความเสี่ยง เราให้บริการซื้อขายสปอตและตราสารอนุพันธ์ รวมถึงฟิวเจอร์ส เพอร์เพตชัวสวอป และออปชันส์ของสกุลเงินดิจิทัลที่สำคัญ ทำให้ผู้ลงทุนมีความยืดหยุ่นอย่างมากในการกำหนดกลยุทธ์เพื่อเพิ่มผลกำไรและลดความเสี่ยง

ข้อมูลติดต่อสำหรับสื่อ
Vivien Choi
media@okex.com

UK Study Tests Form of Ibuprofen as Coronavirus Treatment

 

A form of ibuprofen called flarin is being studied in Britain to see if it is effective for treating COVID-19 respiratory symptoms caused by the coronavirus.

Also called lipid ibuprofen, flarin has anti-inflammatory effects and is designed to shield the stomach from irritation when taken.

The study, LIBERATE Trial in COVID-19, aims to test flarin on 230 people who have been hospitalized due to COVID-19 and have acute respiratory failure. Only patients who are 18 or older are eligible.

COVID-19 patients who have shown hypersensitivity to other non-steroidal anti-inflammatory drugs (NSAIDS) do not qualify for the study.

Ibuprofen received attention in March, when French Health Minister Olivier Veran tweeted that NSAIDS, which include ibuprofen, could aggravate COVID-19 symptoms.

Since then, the World Health Organization, European Medicines Agency and other groups said there was not enough evidence to prove ibuprofen would worsen COVID-19 symptoms.

The sponsor of the LIBERATE study is King’s College London, with the Guy’s and St. Thomas NHS Foundation Trust as the collaborator.

The estimated date for initial results is Sept. 25, 2020, and the final estimated study completion date is May 25, 2021.

 

Source: Voice of America

 

Study: Trump’s Favored COVID Drug Did Not Prevent Infection

Hydroxychloroquine, the drug U.S. President Donald Trump took to prevent COVID-19 against the advice from the U.S. Food and Drug Administration, failed to prevent infection in a new study.

In the new research, published in The New England Journal of Medicine, people at risk of infection who took hydroxychloroquine were no less likely to develop COVID-19, the disease caused by the coronavirus, than people taking a sugar pill.

“We were a little bit disappointed that obviously it didn’t work,” said study lead David Boulware of the University of Minnesota.

Other studies have suggested that the drug does not help treat patients already sick with COVID-19, either, though questions surround those studies.

 

Doctors had hoped that hydroxychloroquine, a cheap and widely available drug for malaria, lupus and rheumatoid arthritis, might work against the coronavirus based on test tube studies. Small, early studies also seemed to show the drug helped treat sick COVID-19 patients.

But other scientists questioned those results and urged caution. The publisher of one of the most influential early reports has since said the study does not meet its standards.

With nothing else available to help COVID-19 patients, “many thousands of people were treated with it in the hope that it would do some good but in the absence of any really valid evidence that it worked,” Johns Hopkins University epidemiologist Richard Chaisson said.

Chaisson was not involved in the prevention study, but he is leading separate research on hydroxychloroquine to treat hospitalized COVID-19 patients.

No difference

The new prevention trial involved about 800 people who had been exposed to someone with a laboratory-confirmed case of COVID-19.

Two-thirds were health care workers. The others were caring for infected family members. Half of the participants received hydroxychloroquine. Half received a placebo.

Two weeks after exposure, there wasn’t much difference between the two. About 12% of those taking hydroxychloroquine developed COVID-19, compared to about 14% of those taking a placebo.

“It would be great to have a preventive therapy,” Boulware said. “Based on our trial, we would say that hydroxychloroquine is not the medicine that’s going to do that.”

About 40% of patients taking hydroxychloroquine had nausea, upset stomachs, diarrhea or other negative reactions.

None had serious side effects. Patients in some other studies developed heart problems, leading the FDA to caution against its use for COVID-19 outside clinical trials.

Hype

“One unfortunate thing that has happened here is there has been a lot of hype about this drug,” and it’s getting in the way of good science, Chaisson said.

Trump has been advocating for it since March. Last month he said he was taking the drug after his personal valet tested positive for the coronavirus. Popular conservative media commentator Laura Ingraham has called hydroxychloroquine a “game changer.”

recent study found that the drug did not help treat COVID-19 patients and may have done harm.

But it was not designed to provide definitive answers. And after criticism from other scientists about the data, the publisher issued an “expression of concern” and commissioned an audit of the research.

That means it’s still not settled whether hydroxychloroquine helps treat COVID-19.

On the other hand, the new study provides strong evidence that it does not prevent infection.

“This is the first really well-done comparative study,” said Harvard Medical School infectious-disease physician Raj Gandhi, who helped write the Infectious Diseases Society of America’s COVID-19 treatment guidelines for physicians.

But there’s more work to do, he added.

“The message shouldn’t be that the studies for treatment should stop,” he said. “You’re actually obligated to do a study because otherwise you will never know an answer. And we really need to know an answer.”

 

Source: Voice of America

Sweden’s Första AP-fonden (AP1) Selects eVestment for Asset Manager Monitoring

STOCKHOLM, Sweden and LONDON, June 03, 2020 (GLOBE NEWSWIRE) — Swedish public pension fund Första AP-fonden (AP1) will add to its asset manager selection capabilities by adopting asset manager monitoring capabilities from eVestment, a global leader in institutional investment data and analytics.

As pensions around the world search for investment returns at acceptable levels of risk, data providers like eVestment have an important role in collecting and organizing data used in the manager assessment and monitoring processes. With 4000+ asset managers from around the world reporting data to eVestment on more than 25,000 institutional strategies, eVestment offers the most comprehensive look at trends across the institutional landscape, at the universe, firm and product levels.

“As a leading source of institutional manager data, both in local markets and globally, eVestment provides a holistic view of the managers and strategies available,” said eVestment Managing Director for EMEA J.P. Quittot. “This power to find the best managers in the world and effectively hold those managers accountable through regular monitoring is important as pensions, the pensioners they serve, regulatory bodies and other stakeholders look for more transparency in the management of pension money.”

AP1 has assets of SEK 365.8 billion (approximately US$37 billion) distributed across a global portfolio consisting of equities, fixed-income securities, real estate, infrastructure, private equity funds and hedge funds.

AP1 will incorporate eVestment data into its existing process for monitoring its current roster of managers and for continual monitoring of managers on their shortlist. This will give AP1 insights into how those managers are performing if AP1 seeks to rebalance or reallocate in the future.

Asset managers seeking to maximize their visibility in databases and ensure they’re providing the data to investors like AP1 are encouraged to reach out to eVestment at www.evestment.com or ClaireSpencer@eVestment.com to learn more. Asset managers currently working with AP1 and those hoping to in the future are encouraged to ensure their eVestment firm and product profiles are fully populated on a timely basis each quarter.

About Första AP-fonden
Första AP-fonden (AP1) is one of five pension funds in the Swedish national income pension system (the AP Funds). AP1 has assets under management of SEK 366 billion (31 December 2019) in a portfolio consisting of listed equities, fixed income securities, currency, real estate, hedge funds, private equity funds, infrastructure and high yield. Investments are made worldwide. AP1 is a long-term investor and an active, engaged owner. As an owner the Fund imposes stringent demands in the areas of Environment, Social and Governance. www.ap1.se

About eVestment

eVestment, a Nasdaq company, provides institutional investment data, analytics and market intelligence covering public and private markets. Asset managers and general partners reach the institutional marketplace through our platform, while institutional investors and consultants rely on eVestment for manager due diligence, selection and monitoring. eVestment brings transparency and efficiency to the global institutional market, equipping managers, investors and consultants to make data-driven decisions, deploy their resources more productively and ultimately realize better outcomes.

Press Contact
Mark Scott
mscott@evestment.com
678 238 0761

Nokia and Elisa see sustainability leap in world-first 5G liquid cooling deployment

Nokia and Elisa see sustainability leap in world-first 5G liquid cooling deployment

  • Nokia only vendor to offer liquid cooling base station solution across all network generations
  • Liquid-cooled 5G AirScale Base Station is yet another milestone in Nokia’s commitment to sustainability and combatting climate change
  • The solution allows operators to cut their BTS site energy expenses by 30% and CO2 emissions by 80%

3 June 2020

Espoo, Finland – Nokia today announced that its liquid cooling 5G AirScale Base Station solution has helped Finnish mobile operator, Elisa, reduce the potential energy expenses of its base station by 30 percent and CO2 emissions by approximately 80 percent. This is the first time a commercial 5G liquid cooling solution has been deployed anywhere in the world and highlights Nokia’s strong commitment to sustainability and combatting climate change.

The Nokia Bell Labs-developed solution will enable Elisa to achieve 30 percent lower power consumption and related savings at its site in Helsinki, Finland. Approximately 90 percent of energy consumed by base stations is converted to waste heat, however, with a heat re-use option – where waste heat is converted and repurposed – Elisa has been able to reduce its CO2 emissions by approximately 80 percent.

Liquid-cooled sites are silent, require zero maintenance, and can be 50 percent smaller and 30 percent lighter than standard active air conditioning units. They offer operators and owners of base station sites significant savings and potentially longer base station component life.

Technology innovation plays a key role in achieving a more sustainable planet and better,
healthier lives for all people. Liquid cooling is another example of Nokia’s long-standing commitment to sustainability. In 2019, the company delivered zero-emission products to over 150 customers worldwide. It is also committed to decreasing emissions from its operations by 41 percent by 2030. 46 percent less energy was used on average in the customer base station sites Nokia modernized in 2019 compared to those where its customers did not modernize. Last year, Nokia also joined a group of 87 companies at the United Nations climate summit in committing to recalibrate its existing science-based climate targets in line with the 1.5°C warming scenario.

Sami Komulainen, Executive Vice President of Production at Elisa, said: “Elisa has set a clear target to be carbon neutral at the end of 2020. We also want to maintain our 5G leadership and continue to be amongst the top operators in the world to offer the wide benefits of this new technology to our customers. Innovations such as Nokia’s liquid cooling 5G base station demonstrate how 5G can help drive sustainability.”

Tommi Uitto, President of Mobile Networks at Nokia, said: “Our greatest contribution to overcoming the world’s sustainability challenges is through the solutions and technology we develop and provide. Nokia was first to introduce a liquid-cooled base station with the 2G, 3G and 4G base stations with Elisa in Finland. Now we have demonstrated the world’s first liquid-cooled AirScale 5G base station in commercial operations, making liquid cooling a reality for all network generations. This innovative solution supports operators in their quest to be more environmentally responsible while allowing them to achieve significant cost savings.”

Resources:

About Nokia
We create the technology to connect the world. Only Nokia offers a comprehensive portfolio of network equipment, software, services and licensing opportunities across the globe. With our commitment to innovation, driven by the award-winning Nokia Bell Labs, we are a leader in the development and deployment of 5G networks.

Our communications service provider customers support more than 6.4 billion subscriptions with our radio networks, and our enterprise customers have deployed over 1,300 industrial networks worldwide. Adhering to the highest ethical standards, we transform how people live, work and communicate. For our latest updates, please visit us online www.nokia.com and follow us on Twitter @nokia.

Media Inquiries:
Nokia
Communications
Phone: +358 10 448 4900
Email: press.services@nokia.com

Lupin signs distribution agreements in key EU territories for orphan drug NaMuscla®

Lupin signs distribution agreements in key EU territories for orphan drug NaMuscla®

Enables expanded patient access of rare disease medicine to treat myotonia symptoms in non-dystrophic myotonic disorders in three key territories

Zug, Switzerland, 3 June: Lupin is pleased to announce that it has entered into distribution agreements with three companies for its orphan drug NaMuscla® (mexiletine). Exeltis Healthcare S.L, Cresco Pharma B.V and Macure Pharma ApS will commercialize NaMuscula® for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders in certain EU territories. NaMuscula® is the first and only licensed product for this indication.

NDM disorders are a group of rare, inherited neuromuscular disorders which cause the inability to relax muscles following voluntary contraction. NaMuscla® reduces myotonia symptoms in adult patients, resulting in a significant improvement in patient quality-of-life and other functional and clinical outcomes1. NaMuscla®, which has been designated orphan drug status, received EU marketing authorization in December 2018.

Under the agreements announced today, Exeltis Healthcare S.L will commercialize NaMuscla® in Spain and Portugal, Cresco Pharma B.V will commercialize NaMuscla® in the Netherlands and Macure Pharma ApS in the Nordic countries. Lupin will continue commercialization of NaMuscula ® in Germany and UK and will launch the product in Austria and France later this year.

“These distribution agreements represent an important milestone for Lupin as we roll out commercialization of NaMuscla® across Europe. Collaborating with partners that are highly effective in their focus territories ensures patients will receive the drug in as effective manner as possible,” said Thierry Volle, President EMEA, Lupin. “Lupin is committed to addressing the unmet needs of patients with NDM through the establishment of country-specific solutions and to ensuring patient access across Europe in alignment with national health authorities, healthcare providers and patient advocacy groups.”

Today, more than 7,500 people in Europe2,3,4 living with NDM have limited access to a licensed treatment for myotonia that can reduce the daily burden of this disabling, lifelong symptom. Limited access leads to inconsistent medication supply, administrative challenges and associated financial burdens, which, along with low awareness and limited clinical experience among healthcare professionals due to rare nature of disease, may result in significant harm to patients5. Lupin recently obtained approvals to begin a paediatric trial as part of the paediatric investigation plan for NaMuscla® and a post authorisation [safety] study to address long-term safety and treatment efficaciousness on patient reported outcomes. Both trials will begin later this year.

For further information or queries please contact:

Consilium Strategic Communications
Amber Fennell / Sukaina Virji / Lizzie Seeley
Tel: +44 (0)20 3709 5700
Email: lupin@consilium-comms.com

Notes for Editors

About Myotonic Disorders and Non-Dystrophic Myotonic (NDM) Disorders
Myotonic disorders are a group of heterogeneous, inherited, neuromuscular disorders characterized by a shared symptom called myotonia. Myotonia can be described as an inability to relax a contraction of skeletal muscle which originates from a voluntary muscular contraction such as shaking someone’s hand and blinking, or everyday activities such as walking across a street and climbing stairs.

Non-dystrophic myotonias (NDM) are a sub-set of rare (prevalence of 1:100,0004), inherited, myotonic disorders which are caused by mutations within ion channels in the sarcolemma membrane of skeletal muscles. Non-dystrophic myotonias exhibit both sodium and chloride channelopathies which result in altered membrane excitability. For patients with NDM, myotonia is the most prominent symptom and demonstrates different phenotypes in subgroups of NDM disorders, and can affect different parts of the body, such as legs, arms or facial muscles, more severely.

Myotonia in NDM patients has an onset in childhood and persists across their lifetime.  Patients perceive that myotonia increases in severity over time, impacting daily life. Myotonia is described by patients in a variety of ways (stiffness, cramps, pain, difficulty releasing a fist, or difficulty swallowing or eating) which can contribute to substantial delays in diagnosis and treatment, leading to decreased patient quality-of-life and often significant disability.

About NaMuscla® (mexiletine)
NaMuscla® is the first and only antimyotonic agent licensed to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders across Europe. In randomized controlled trials, NaMuscla® (167 to 500 mg/day) has been shown to significantly reduce myotonia compared to placebo, reducing skeletal muscle hyperexcitability through its use-dependent, voltage-gated, sodium channel blocking actions which are independent of the cause of channel function. This resulted in an improvement in patient quality-of-life and other functional outcomes, with gastro-intestinal discomfort reported as the most common adverse event, demonstrating NaMuscla® to be safe and well tolerated1.

About Lupin Limited
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership positions in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information. Follow us on Twitter | LinkedIn | Facebook

About Exeltis Healthcare S.L
Exeltis is a fast-growing division of the integrated health sciences group Insud Pharma. With a global footprint spanning over 40 countries, Exeltis has a team of more than 4,000 professionals supported by a global manufacturing network. It boasts a leadership position in the Women’s Health segment, and in recent years, Exeltis has also diversified into Central Nervous System (CNS), Ophthalmology and Endocrinology. Exeltis is constantly innovating and seeking new treatments and devices to improve patients health and wellbeing around the world.

About Cresco Pharma B.V
Cresco Pharma B.V. is a privately owned Dutch pharmaceutical company founded in 2008. The company is headquartered in Meerssen, the Netherlands. Cresco commercializes a range of products for the treatment of severe chronic patients. The company is focusing on the commercialization of respiratory products and neurology products. The mission is to improve care for patients by the distribution of best in class products and services. The company is key player in distributing combinations of inhaled antibiotics with fast nebulizer systems to contribute to improved patient adherence. Also in the treatment of advanced Parkinson’s disease, the company recently introduced a next generation of drug and pump therapy. Cresco Pharma is managed by an experience board of directors and has small dedicated team with focused on caregivers in hospitals.

About Macure Pharma ApS
Macure Pharma is a rapidly growing, Nordic specialty company focused on niche pharmaceuticals. The company’s head office is in Copenhagen, Denmark. Macure Pharma has a full presence in each of the Nordic countries (Denmark, Norway, Finland & Sweden) with separate warehousing, distribution & sales force in each market.